Addiction

SAS and Clemson University deploy AI and machine learning software for education and research

Retrieved on: 
Thursday, March 24, 2022
Foundation (nonprofit), Data management, Information technology, Public sector, College, STEM, Data science, Extension, Adult, Education, SAS, Clemson, Clemson University, Faculty, Research, Program, University of Houston–Downtown College of Sciences and Technology, Doctor of Philosophy, Academic specialization, Intelligence, Addiction, Secretary of State of South Carolina, Name, Agriculture, Genome, Academy, Software, Artificial intelligence, Museum, Wildlife disease, Technology, Carnegie Foundation, SAS Institute Inc v World Programming Ltd, Literacy, Machine learning, SAS Institute, Student, Solution, Highlander Research and Education Center, Peripheral artery disease, POWER, University, Partnership, Tutoring, Satellite navigation device

CARY, N.C., March 24, 2022 /PRNewswire/ -- Clemson students and faculty will have access to powerful data science and analytics software from SAS thanks to a new, $3.3 million donation to support teaching and academic research. Extending a 2017 partnership, the latest gift from SAS includes access to SAS® Viya®, the company's flagship artificial intelligence, machine learning, analytics and data management platform.

Key Points: 
  • Extending a 2017 partnership, the latest gift from SAS includes access to SAS Viya, the company's flagship artificial intelligence , machine learning, analytics and data management platform.
  • SAS will also provide teaching materials and on-site training for faculty and staff to help them integrate SAS into coursework and research.
  • The SAS partnership with Clemson creates a competitive edge for students with a knowledge of SAS Viya and other analytics skills.
  • SAS and all other SAS Institute Inc.productor service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries.

Shell Avenue Retains New Life Coach & Program Consultant

Retrieved on: 
Wednesday, March 23, 2022
Couples therapy, Shell, Addiction, Light, Family, International, Darkness, Goal, University of Oxford, CEO, Medicine, Theology

LOS ANGELES, March 23, 2022 /PRNewswire-PRWeb/ -- Shell Avenue , a private therapeutic recovery and personal transformation center is expanding its operations.

Key Points: 
  • LOS ANGELES, March 23, 2022 /PRNewswire-PRWeb/ -- Shell Avenue , a private therapeutic recovery and personal transformation center is expanding its operations.
  • The spiritual growth incubator, known for curated personal growth consulting and addiction-recovery sober living, has retained the consultancy of Benjamin Leyland to provide round-the-clock residential recovery coaching and program management.
  • Founded in 2001 by Sean McFarland, Shell has helped thousands of individuals, couples and families overcome their struggles, confront their demons, and transform their lives.
  • We need more people to continue that mission, which is where Benjamin comes in," says Shell founder and CEO, Sean McFarland.

Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities

Retrieved on: 
Saturday, March 19, 2022
Company, Patent, Mental health, Corona Labs Inc., WKN, Lists of diseases, Research, Addiction, Industry, Technology, Database, GLOBE, Psilocybin, Depression, OTC, Patient, CSE, Pharmaceutical industry

VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the Company or Core One) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.

Key Points: 
  • VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the Company or Core One) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.
  • Acquisition or investment by a major pharmaceutical company could be mutually beneficial.
  • About Core One Labs Inc.
  • Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria.

Northeast Delta HSA Releases Results of Region's Food Insecurity Survey

Retrieved on: 
Thursday, March 17, 2022
Housing, Behavior, Mental health, Health, Transport, Violence, Unemployment, Telephone, Employment, Addiction, Google Forms, COVID-19, Income, Food, Anxiety, Trauma, Depression, Education, Food security, Patient, Medicine

MONROE, La., March 17, 2022 /PRNewswire-PRWeb/ --Northeast Delta Human Services Authority (NEDHSA) announces the results of its Mental Health and Food Insecurity Assessment.

Key Points: 
  • MONROE, La., March 17, 2022 /PRNewswire-PRWeb/ --Northeast Delta Human Services Authority (NEDHSA) announces the results of its Mental Health and Food Insecurity Assessment.
  • NEDHSA conducted the study to provide insight into the region's needs regarding food insecurity, food inadequacy, mental health, and addictive disorder services.
  • NEDHSA Director of Behavioral and Primary Health Analytics Dr. Dependra Bhatta said "our results provide an overview of mental health, physical health, and food insecurity concerns."
  • "Depression, anxiety, and food insecurity are severe among individuals with low income, unemployment, and trauma violence experience."

Impact Suite™ Reveals New Updates to Lift, a Digital Mental Health App

Retrieved on: 
Thursday, March 17, 2022
Fortify, Bangladesh Technical Education Board, Mindfulness, National Suicide Prevention Lifeline, Risk, Mental health, The Trevor Project, Brigham Young University, Overalls, Addiction, App store optimization, Research, App store, Financial management, Q&A, Risk assessment, Thought, Meditation, Industry, Wheatley, SOS, GLOBE, Student, Substance abuse, Anxiety, Depression, Education, Google Play, Impact, Mobile phone, Medicine, Lift

The goal is to create sustainable change for individuals seeking relief from mental health issues, specifically depression and anxiety.

Key Points: 
  • The goal is to create sustainable change for individuals seeking relief from mental health issues, specifically depression and anxiety.
  • Mental health issues are at an all-time high, impacting 1 in 3 Americans, shared Impact Suite CEO Clay Olsen.
  • The research is clear that there are small, simple adjustments in life that can have measurable impact on overall mental health.
  • Impact Suite provides science-based virtual treatment solutions for people facing mental health and addiction issues, focusing on key improvements that have been proven to influence wellbeing.

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Retrieved on: 
Thursday, March 17, 2022
Phrase, SEDAR, Perception, Person, Time, Patient, Addiction, News, Review, Intention, NEO, Therapy, Public opinion, Forward-looking statement, CQC, Mental health, Home, Company, CEO, Genta (company), Ketamine, Industry, FSE, Care Quality Commission, Pharmaceutical industry, Audit, Security (finance)

Toronto, Ontario--(Newsfile Corp. - March 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission's (CQC) formal approval to begin treatments for addiction and mental health.

Key Points: 
  • The flagship London clinic is Awakn's third clinic, adding to the Company's two operating clinics located in Bristol (UK) and Oslo (Norway).
  • Most importantly, it provides an effective treatment option for so many when other current therapies or treatments fall short.
  • Following on from the CQC approval, Awakn will receive a schedule 2 license from the Home Office which will allow ketamine to be administered in the London clinic.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022
Doctor of Philosophy, MD, Depression, Technology, Associate, Patient, Schizophrenia, Oklahoma Medical Research Foundation, CNS, Columbia University Vagelos College of Physicians and Surgeons, Therapy, Post-traumatic stress disorder, Data, Columbia University, Parkinson's disease, Brain, Neuropsychiatry, Physician, Algorithm, Addiction, Biomarker, Alzheimer's disease, PTSD, Research, Mental Hygiene, CEO, Pharmaceutical industry, Terran, Surgeon

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022
Doctor of Philosophy, MD, Depression, Technology, Associate, Patient, Schizophrenia, Oklahoma Medical Research Foundation, CNS, Columbia University Vagelos College of Physicians and Surgeons, Therapy, Post-traumatic stress disorder, Data, Columbia University, Parkinson's disease, Brain, Neuropsychiatry, Physician, Algorithm, Addiction, Biomarker, Alzheimer's disease, PTSD, Research, Mental Hygiene, CEO, Pharmaceutical industry, Terran, Surgeon

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Recovery Centers of America at St. Charles Designated as a Blue Distinction® Center for Substance Use Treatment and Recovery

Retrieved on: 
Wednesday, March 16, 2022
Association, Twitter, Center, MBA, MD, Program, Research, Blue, Opioid, Transplant, Patient, Knee, Korea Disease Control and Prevention Agency, Multimedia, FACEP, Accreditation, Patient safety, High Watch Recovery Center, Blue Cross Blue Shield Association, RCA, ST, Health Care Service Corporation, MAT, Blue Shield, Public relations, Health, Addiction, Blue Cross, Blue Cross (animal charity), Substance, Bariatric surgery, CEO, Instagram, WA, View, LinkedIn, YouTube, Health insurance, Hospital, Facebook, BDC

Blue Cross Blue Shield of Illinois recognizes Recovery Centers of America at St. Charles as a Blue Distinction Center.

Key Points: 
  • Blue Cross Blue Shield of Illinois recognizes Recovery Centers of America at St. Charles as a Blue Distinction Center.
  • "Recovery Centers of America at St. Charles is proud to be recognized as a Blue Distinction Center, as our goal is always to provide innovative, evidence-based treatment by highly experienced and credentialed professionals.
  • Research for many programs shows that, compared to other providers, those designated as Blue Distinction Centers demonstrate better quality and improved outcomes for patients.
  • Recovery Centers of America (RCA) has ten inpatient substance use disorder treatment facilities in the United States.

Eating Disorder Treatment Facility Aster Springs Opens in Richmond, Virginia

Retrieved on: 
Tuesday, March 15, 2022
Odyssey, GLOBE, Eating disorder, Partnership, PHP, Lists of diseases, Hospital, Adult, RTC, IOP, Woman, CEO, Bed, Addiction, Medicine

BRENTWOOD, Tenn., March 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Behavioral Healthcare ("Odyssey"), nationally recognized for eating disorder and mental health treatment, is excited to announce the opening of its newest Eating Disorder Network facility, Aster Springs , an eating disorder treatment center for adult women.

Key Points: 
  • BRENTWOOD, Tenn., March 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Behavioral Healthcare ("Odyssey"), nationally recognized for eating disorder and mental health treatment, is excited to announce the opening of its newest Eating Disorder Network facility, Aster Springs , an eating disorder treatment center for adult women.
  • With this new Richmond treatment facility, Odyssey is expanding its diverse clinical presence in Virginia.
  • Aster Springs addresses a prevalent need by providing individualized eating disorder treatment, multiple levels of care, and a home-like environment set in peaceful surroundings.
  • "The addition of Aster Springs to the Odyssey Eating Disorder Network family is significant in addressing the region's market demand for evidence-based eating disorder clinical care."